IP Library Granted Patent US 9,708,588
Granted Patent B2
US 9,708,588 · App. 15/180,355 · Granted Jul 18, 2017

Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs

Inventors: Jovana Nazor (Santa Clara, CA); Derek J. Smith (Singapore, SG); Michael A. Crowe (Singapore, SG); Shiwei Song (Singapore, SG); Steven J. Collier (Concord, MA)
Assignee: Codexis, Inc.
C12N9/1096C12P17/10C12Y206/01C12Y206/01018Y02P20/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,708,588
App. No.
15/180,355
Granted
Jul 18, 2017
Kind
B2
Abstract

The present disclosure provides engineered transaminase polypeptides for the production of amines, polynucleotides encoding the engineered transaminases, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases to prepare compounds useful in the production of active pharmaceutical agents.

Claims (34)

1. An engineered polynucleotide encoding a polypeptide having transaminase activity, wherein said polypeptide comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 4 and one or more residue differences as compared to SEQ ID NO:4, wherein said polypeptide comprises a substitution at residue position X163L.

2. The engineered polynucleotide of claim 1 , in which the residue differences in said encoded polypeptide having transaminase activity further comprises substitutions at the residue positions X14; X26; X33; X41; X47; X70; X88; X107; X132; X148; X173; X203; X250; X284; X315; X346; X395; X400; X419; X423; X448; and X451, wherein said substitutions are selected from X14V; X26R; X33T; X41L; X47N; X70A; X88A; X88L; X107P; X132F; X148Q; X148R; X173A; X203S; X250A; X284A; X315G; X346L; X395P; X400G; X419S; X423I; X448E; and X451D.

3. The engineered polynucleotide of claim 2 , in which the amino acid sequence of said encoded polypeptide having transaminase activity further comprises one or more residue differences selected from: X57F; X113L; X113V; X168K; X420N; and X424V.

4. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity further comprises at least one or more residue differences selected from: X14V; X26R; X315/D; X86D; X163I/L/R/V; X284A; X315G; X398L/V/W; and X400G.

5. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity further comprises a combination of residue differences selected from:

X14V and X163I/L/R/V;

X86D and X400G;

X57F/Y and X163I/L/R/V;

X57F/Y and X398L/V/W;

X14V, X113L/V, X163I/L/R/V, X284A, and X424V;

X31S, X57F/Y, X163I/L/R/V, X315G, X346L, and X398L/V/W

X14V, X113L, X163L, X284A, and X424V;

X14V, X26R, X163L, X284A, and X400G;

X14V, X26R, X88L, and X113L;

X57F, X163L, X168K, X314N, X315G, X346L, and X398V;

X14V, X163L, X173A, X400G, and X420N;

X14V, X113L, X163L, and X284A;

X14V, X26R, X163L, X284A, and X400G; and

X14V, X33T, X57F, X113L, and X163L.

6. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity has at least 1.2 fold increased stability as compared to the polypeptide of SEQ ID NO:4, wherein the amino acid sequence further comprises one or more residue differences selected from: X14V; X26R; X31S; X33T; X41L; X70A; X86D; X88A/L; X163I/L/R/V; X284A; X324H; X419S; and X423I.

7. The engineered polynucleotide of claim 1 , in which the amino acid sequence of said encoded polypeptide having transaminase activity comprises SEQ ID NO:6.

8. An expression vector comprising the polynucleotide of claim 1 .

9. The expression vector of claim 8 , further comprising at least one control sequence.

10. The expression vector of claim 9 , wherein said control sequence comprises a promoter.

11. A host cell comprising the polynucleotide of claim 1 .

12. A host cell comprising the expression vector of claim 8 .

13. A host cell comprising the expression vector of claim 9 .

14. A host cell comprising the expression vector of claim 10 .

15. The host cell of claim 11 , wherein said host cell is E. coli.

16. The host cell of claim 12 , wherein said host cell is E. coli.

17. The host cell of claim 13 , wherein said host cell is E. coli.

18. The host cell of claim 14 , wherein said host cell is E. coli.

19. A method of preparing an engineered polypeptide having transaminase activity, comprising culturing the host cell of claim 11 under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.

20. A method of preparing an engineered polypeptide having transaminase activity, comprising culturing the host cell of claim 12 under conditions suitable for expression of the polypeptide, optionally further comprising isolating the engineered polypeptide.

Assignments (1)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
Continuity (4)
Division 14828839 · Aug 18, 2015
Division 14386082
Provisional Application 61614666 · Mar 23, 2012
Related Publication 20160289649A1 · Oct 6, 2016